Compare Oscar Health Inc (OSCR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs Smith & Nephew plc — how do they compare? Oscar Health Inc trades at $33.37 (market cap $10.22B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Oscar Health Inc and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.95% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Smith & Nephew plc for 121 Days on average.
| OSCR | SNN | |
|---|---|---|
Market Cap | $10.22B | $11.10B |
Volume | 4,123,394 | 1,051,703 |
Sector | Health | Health |
52-Week High | $33.81 | $37.17 |
52-Week Low | $10.85 | $26.42 |
Typical Hold Time | 15 Days | 121 Days |
Enterprise Value | $6.57B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $33.37, up 1.4% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, turning profitable with $551M net income. Recent Q1 and Q2 2026 earnings beat expectations, while analyst consensus leans toward Hold (61.54%) with a $34 price target. Technical indicators show bullish signals but RSI suggests potential overbought conditions near-term.
Outlook remains positive with scalable ACA market growth and margin expansion driving earnings potential. Key risks include rising medical costs threatening profitability and competitive pressures. The stock offers growth exposure but requires monitoring of execution on 2029 EPS targets of $4+ and medical loss ratio management.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
